THE WIRE · № 61584
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt
01 THE MACHINE READ
WHY IT MATTERS.
A dual GLP-1/GIP agonist showing 19.3% weight loss at week 48 intensifies competition in the obesity-drug market dominated by LLY and NVO.
Hansoh obesity candidate posts strong Phase III data
Full EASD data and regulatory filings
Company-presented data, not yet peer-reviewed
FULL DISPATCH
MAILAND, 2. Oktober 2026 /PRNewswire/ -- Vom 28. September bis zum 2. Oktober 2026 findet in Mailand, Italien, die Jahrestagung der Europäischen Vereinigung für die Erforschung von Diabetes (EASD) statt. Olatorepatid (HS-20094), ein von Hansoh Pharma selbst entwickelter dualer Agonist der...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy2026-10-02 10:00 UTC
Interim Phase 2 Results from First-in-Class Combination of Invikafusp Alfa and TRODELVY® Selected for Oral Presentation at SITC 20262026-10-02 11:00 UTC
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals2026-10-02 11:18 UTC
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 10:57 UTC
Afya (AFYA) Stock Looks Cheap Following A Fresh Merger Agreement2026-10-02 11:45 UTC
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage2026-10-02 12:15 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.